Prothena/$PRTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prothena
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Ticker
$PRTA
Sector
Trading on
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
163
ISIN
IE00B91XRN20
Website
Prothena Metrics
BasicAdvanced
$253M
-
-$2.05
0.10
-
Price and volume
Market cap
$253M
Beta
0.1
52-week high
$25.42
52-week low
$4.32
Average daily volume
2M
Financial strength
Current ratio
9.001
Quick ratio
8.625
Long term debt to equity
1.731
Total debt to equity
2.331
Management effectiveness
Return on assets (TTM)
-15.49%
Return on equity (TTM)
-23.46%
Valuation
Price to revenue (TTM)
1.833
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-1.936
Growth
Revenue change (TTM)
54.55%
Earnings per share change (TTM)
-36.43%
3-year revenue growth (CAGR)
-11.88%
3-year earnings per share growth (CAGR)
15.17%
What the Analysts think about Prothena
Analyst ratings (Buy, Hold, Sell) for Prothena stock.
Prothena Financial Performance
Revenues and expenses
Prothena Earnings Performance
Company profitability
Prothena News
AllArticlesVideos
Why Is Prothena Stock Trading Lower On Tuesday?
Benzinga·3 days ago
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
Business Wire·1 week ago
Prothena to Report First Quarter 2025 Financial Results on May 8
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prothena stock?
Prothena (PRTA) has a market cap of $253M as of May 30, 2025.
What is the P/E ratio for Prothena stock?
The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of May 30, 2025.
Does Prothena stock pay dividends?
No, Prothena (PRTA) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Prothena dividend payment date?
Prothena (PRTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Prothena?
Prothena (PRTA) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.